Research Article Efficacy of Nanocurcumin as an Add-On Treatment for Patients Hospitalized with COVID-19: A Double-Blind, Randomized Clinical Trial Sedigheh Ahmadi , 1 Zeinab Mehrabi , 2 Morteza Zare , 3 Sara Ghadir , 1 and Seyed Jalil Masoumi 3,4,5 1 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran 2 Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran 3 Nutrition Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran 4 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran 5 Center for Cohort Study of SUMS Employees’ Health, Shiraz University of Medical Sciences, Shiraz, Iran Correspondence should be addressed to Seyed Jalil Masoumi; masoumi7415@gmail.com Received 6 December 2022; Revised 20 April 2023; Accepted 16 July 2023; Published 28 July 2023 Academic Editor: Leandro Napier de Souza Copyright © 2023 Sedigheh Ahmadi et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Curcumin is a polyphenol derivative of the Curcuma longa rhizome, with potential antioxidant, anticancer, an• tidepressant, antiviral, and anti•infammatory efects. Tis compound can be prepared as biodegradable polymer nanoparticles, called nanocurcumin, to improve its solubility, stability, half•life, and bioavailability. Aim. We explored nanocurcumin’s efect on the clinical manifestations of patients hospitalized with mild•to•moderate COVID•19. Methods. Tis double•blind, randomized clinical trial involved 76 COVID•19 patients admitted to Ali•Asghar Hospital from December 2021 to March 2022. All patients received standard coronavirus treatment as per national guidelines. In addition, four times a day for two weeks, the curcumin group received 40 mg of nanocurcumin, while the control group received a placebo. Clinical manifestations were examined and recorded by the associate doctors working in the department. Statistical analysis was done using SPSS v. 21. Results. Tirty•nine people from the control group and 29 from the curcumin group completed the study. At baseline, the groups were comparable in age, gender, body mass index, hospitalization duration, and background diseases. Te mean age of patients in the control and treatment groups was 53.9 ± 11.9 and 54.6 ± 13.4, respectively. Compared with the placebo, nanocurcumin minimized coughs (P � 0.036), fatigue (P � 0.0001), myalgia (P � 0.027), oxygen demand (P � 0.036), oxygen usage (P � 0.05), and respiratory rate (P < 0.0001). By discharge, the curcumin group had a signifcantly greater increase in SPO 2 than the control group (P � 0.006). Conclusions. Tis preliminary study suggests that nanocurcumin has a potentiating anti•infammatory efect when combined with standard COVID•19 treatment, helping the recovery from the acute infammatory phase of the disease in hospitalized patients with mild•to•moderate disease severity. Tis trial is registered with Iranian Registry of Clinical Trials: IRCT20211126053183N1 (registered while recruiting on 13/12/2021). 1. Introduction Te coronavirus disease 2019 (COVID•19) pandemic has afected roughly 567 million people to date [1]. Presentations vary from mild fu•like symptoms to acute respiratory distress syndrome and death. Fever, fatigue, and cough are the most common symptoms among patients with mild COVID•19. In contrast, chest pain, difculty in breathing, and hypoxia are common symptoms in moderate and severe cases. Te disease may cause acute respiratory distress syndrome (ARDS), total organ failure, and death [2]. Te immune system response causes a hazardous phenomenon called cytokine storms by producing plentiful amounts of infammatory cytokines [3]. Tis cytokine release syndrome Hindawi International Journal of Clinical Practice Volume 2023, Article ID 5734675, 7 pages https://doi.org/10.1155/2023/5734675